A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma

Trial Profile

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Bendamustine (Primary) ; Ublituximab (Primary) ; Umbralisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms UNITY-NHL
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 10 Aug 2017 According to a TG Therapeutics media release, based on pre-specified efficacy thresholds of ORR, the DSMB recommended the Company cease enrollment into the single agent TGR-1202 arm, while continuing enrollment into the TG-1101 + TGR-1202 arm which has demonstrated an acceptable level of efficacy to warrant continued evaluation.
    • 28 Jun 2017 Planned number of patients changed from 200 to 500.
    • 28 Jun 2017 This study now includes patients with Diffuse Large B-cell Lymphoma along with Non-Hodgkin's Lymphoma, Follicular, Small Lymphocytic and Marginal Zone Lymphoma. Thus accordingly changes in scientific title with acronym, inclusion-exclusion criteria and indications. Patients are now receiving treatment of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone. Thus accordingly changes in purpose, treatment arms, patient no etc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top